Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.50 |
| ▸ | MMP2 | P08253 | 5/20 | 0.45 |
| ▸ | MMP1 | P03956 | 4/20 | 0.45 |
| ▸ | MMP3 | P08254 | 4/20 | 0.45 |
| ▸ | MMP7 | P09237 | 4/20 | 0.45 |
| ▸ | MMP9 | P14780 | 4/20 | 0.45 |
| ▸ | MMP13 | P45452 | 4/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 3/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5522107 | 1.00 | CTSK (0.50) | CTSKMMP2MMP1MMP3MMP7 | |
| SCHEMBL5512480 | 0.85 | CHRM2 (0.43) | CTSKMMP2MMP1MMP3MMP7 | |
| SCHEMBL5512484 | 0.85 | CHRM2 (0.43) | CTSKMMP2MMP1MMP3MMP7 | |
| SCHEMBL5512913 | 0.84 | CTSK (0.67) | CTSKCTSSCTSLCTSB | |
| SCHEMBL5512914 | 0.84 | CTSK (0.67) | CTSKCTSSCTSLCTSB | |
| SCHEMBL5510848 | 0.83 | FPR2 (0.39) | CTSKMMP2MMP1MMP3MMP7 | |
| SCHEMBL5516590 | 0.83 | PPARG (0.48) | CTSKMMP2MMP1MMP3MMP7 | |
| SCHEMBL6168522 | 0.83 | PPARG (0.48) | CTSKMMP2MMP1MMP3MMP7 | |
| SCHEMBL5516586 | 0.83 | PPARG (0.48) | CTSKMMP2MMP1MMP3MMP7 | |
| SCHEMBL5520701 | 0.81 | FPR2 (0.42) | CTSKMMP2MMP1MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279478-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2007-10-09 | — | — | US | disclosed |
| US-20060122268-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-06-08 | — | — | US | disclosed |
| EP-1537074-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022526-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122268-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSK | CTSK 3/4885MMP2 113/4885MMP1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.